Trials / Recruiting
RecruitingNCT07098052
A Study of HDM2020 in Patients With Advanced Solid Tumors
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of HDM2020 (FGFR2b-ADC) in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to learn if the study drug can work in advanced cancer patients. The main questions it aims to answer are: * Is the drug safe and tolerable ? * Does the drug exhibit antitumor activity ? Participants will receive the study drug once every three weeks, and imaging-based efficacy assessments will be performed every six weeks.
Detailed description
Target population are patients with FGFR2-expressing solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HDM2020 | FGFR2b-ADC |
Timeline
- Start date
- 2025-08-11
- Primary completion
- 2026-09-30
- Completion
- 2027-05-30
- First posted
- 2025-08-01
- Last updated
- 2025-08-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07098052. Inclusion in this directory is not an endorsement.